Cellbyte

Cellbyte is a vertical AI product, not a general-purpose assistant, and that distinction is most of its case. The core asset is a proprietary database assembled from 100+ regulatory, HTA, and pricing sources — EMA, FDA, HAS, G-BA among them — with every answer traceable to a specific passage in the original filing. For P&MA work, traceability is not a nice-to-have: a pricing recommendation a committee can't audit is a pricing recommendation that never reaches the committee. The four modules map cleanly onto how access teams actually work. Drug Explorer gives the structured cross-market view; Document Intelligence handles long multilingual filings that are slow to read and easy to misread; Agentic Workflows run the recurring comparator and monitoring tasks with a human in the loop; the Data Vault closes the loop by letting you benchmark your own launch data against external intelligence without exporting it. The stated use cases — EU5 HTA-to-price mapping, competitor approval timeline tracking, outcomes validation before submission — are the right ones, and the published case studies quantify the draw: a Lilly Deutschland oncology project reporting a 75% reduction in research time, and a top-20 pharma study reporting 93%. Treat vendor-reported time savings as directional, not audited. Strengths: domain specificity, source attribution as a first-class feature, a real data moat rather than a prompt wrapper, and compliance credentials that pass pharma procurement scrutiny (GDPR, ISO/IEC 27001:2022, SOC 2 Type II in progress). The services arm is an underrated differentiator — teams that want the answer delivered, not just tooling, can buy expert-led deliverables. Weaknesses and open questions: this is contact-only enterprise software, so evaluation cost is real and you should expect a scoped pilot rather than a same-day signup; SOC 2 Type II is still in progress, which matters if your security review requires the attestation today; the underlying model stack isn't published, so you're trusting the vendor's evaluation claims rather than being able to benchmark models yourself; and scope is deliberately narrow — Cellbyte reads regulatory, HTA, and pricing material, not real-time clinical trial data. Where it fits: mid-to-large pharma with an existing P&MA or HEOR function and enough HTA history for benchmarking to be meaningful. Where it doesn't: small biotechs with no dedicated access function, general life-sciences researchers wanting clinical data, and anyone outside healthcare. The honest framing is that Cellbyte sells depth in one function rather than breadth across many — if that function is yours, the trade is straightforward.